Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
Health Res Policy Syst ; 21(1): 33, 2023 May 02.
Article in English | MEDLINE | ID: covidwho-2318462

ABSTRACT

Despite the high burden of mental disorders in low- and middle-income countries (LMICs), less than 25% of those in need have access to appropriate services, in part due to a scarcity of locally relevant, evidence-based interventions and models of care. To address this gap, researchers from India and the United States and the Indian Council of Medical Research (ICMR) collaboratively developed a "Grantathon" model to provide mentored research training to 24 new principal investigators (PIs). This included a week-long didactic training, a customized web-based data entry/analysis system and a National Coordination Unit (NCU) to support PIs and track process objectives. Outcome objectives were assessed via scholarly output including publications, awards received and subsequent grants that were leveraged. Multiple mentorship strategies including collaborative problem-solving approaches were used to foster single-centre and multicentre research. Flexible, approachable and engaged support from mentors helped PIs overcome research barriers, and the NCU addressed local policy and day-to-day challenges through informal monthly review meetings. Bi-annual formal review presentations by all PIs continued through the COVID-19 pandemic, enabling interim results reporting and scientific review, also serving to reinforce accountability. To date, more than 33 publications, 47 scientific presentations, 12 awards, two measurement tools, five intervention manuals and eight research grants have been generated in an open-access environment. The Grantathon is a successful model for building research capacity and improving mental health research in India that could be adopted for use in other LMICs.


Subject(s)
Biomedical Research , COVID-19 , Humans , United States , Mentors , Pandemics , Biomedical Research/education , Mental Health
2.
Indian J Med Res ; 155(5&6): 513-517, 2022.
Article in English | MEDLINE | ID: covidwho-2281625

ABSTRACT

COVID-19 was declared a pandemic by the World Health Organization (WHO) on March 11, 2020. Since then, efforts were initiated to develop safe and effective vaccines. Till date, 11 vaccines have been included in the WHO's emergency use list. The emergence and spread of variant strains of SARS-CoV-2 has altered the disease transmission dynamics, thus creating a need for continuously monitoring the real-world effectiveness of various vaccines and assessing their overall impact on disease control. To achieve this goal, the Indian Council of Medical Research (ICMR) along with the Ministry of Health and Family Welfare, Government of India, took the lead to develop the India COVID-19 Vaccination Tracker by synergizing three different public health databases: National COVID-19 testing database, CoWIN vaccination database and the COVID-19 India portal. A Vaccine Data Analytics Committee (VDAC) was constituted to advise on various modalities of the proposed tracker. The VDAC reviewed the data related to COVID-19 testing, vaccination and patient outcomes available in the three databases and selected relevant data points for inclusion in the tracker, following which databases were integrated, using common identifiers, wherever feasible. Multiple data filters were applied to retrieve information of all individuals ≥18 yr who died after the acquisition of COVID-19 infection with or without vaccination, irrespective of the time between vaccination and test positivity. Vaccine effectiveness (VE) against the reduction of mortality and hospitalizations was initially assessed. As compared to the hospitalization data, mortality reporting was found to be much better in terms of correctness and completeness. Therefore, hospitalization data were not considered for analysis and presentation in the vaccine tracker. The vaccine tracker thus depicts VE against mortality, calculated by a cohort approach using person-time analysis. Incidence of COVID-19 deaths among one- and two-dose vaccine recipients was compared with that among unvaccinated groups, to estimate the rate ratios (RRs). VE was estimated as 96.6 and 97.5 per cent, with one and two doses of the vaccines, respectively, during the period of reporting. The India COVID-19 Vaccination Tracker was officially launched on September 9, 2021. The high VE against mortality, as demonstrated by the tracker, has helped aid in allaying vaccine hesitancy, augmenting and maintaining the momentum of India's COVID-19 vaccination drive.


Subject(s)
COVID-19 , Vaccines , Humans , COVID-19 Vaccines , COVID-19/epidemiology , COVID-19/prevention & control , SARS-CoV-2 , COVID-19 Testing
3.
Indian J Med Res ; 155(1): 86-90, 2022 01.
Article in English | MEDLINE | ID: covidwho-2201765

ABSTRACT

To implement the strategy of test, track and treat to tackle the ongoing COVID-19 pandemic, the number of real-time RT-PCR-based testing laboratories was increased for diagnosis of SARS-CoV-2 in the country. To ensure reliability of the laboratory results, the Indian Council of Medical Research initiated external quality assessment (EQA) by deploying inter-laboratory quality control (ILQC) activity for these laboratories by nominating 34 quality control (QC) laboratories. This report presents the results of this activity for a period of September 2020 till November 2020. A total of 597 laboratories participated in this activity and 86 per cent of these scored ≥90 per cent concordance with QC laboratories. This ILQC activity showcased India's preparedness in quality diagnosis of SARS-CoV-2.


Subject(s)
COVID-19 , SARS-CoV-2 , COVID-19/diagnosis , COVID-19 Testing , Clinical Laboratory Techniques/methods , Humans , Pandemics , Reproducibility of Results , Reverse Transcriptase Polymerase Chain Reaction , SARS-CoV-2/genetics
4.
Frontiers in public health ; 10, 2022.
Article in English | EuropePMC | ID: covidwho-1980695

ABSTRACT

For containment of COVID-19, most countries are following the isolate, test, treat and trace approach. Following the approach, India scaled up COVID-19 testing from about 5,000 tests per day at the end of March 2020 to more than 1 M tests per day in September 2020. Testing scale-up has seen a huge variation across states and union territories (UTs) with respect to growth rates, testing strategies, testing infrastructure, and deployment of various kit types (RT-PCR, Antigen, CBNAAT, etc). To understand the gaps in testing and prioritize appropriate interventions, it is important for national stakeholders to evaluate and rank states/UTs based on their testing performance. Indicators like total samples tested, total samples positive, tests per million, and positives per million are currently being used by epidemiologists and researchers for comparing the performance of various regions. This article proposes a robust ranking methodology to rank the states/UTs in India based on a comprehensive scoring developed by combining multiple variables for evaluating the testing performance of states/UTs. Since RT-PCR testing is considered the gold standard for COVID-19 testing, the composite score for testing performance in this article is defined by the ability of states/UTs to successfully deploy RT-PCR testing and reduce its positivity over time. Evaluating region-wise ranking can enable the identification of areas requiring immediate attention in poorly performing regions, thus channelizing efforts and resources in the right direction.

5.
PLoS One ; 17(2): e0263736, 2022.
Article in English | MEDLINE | ID: covidwho-1674020

ABSTRACT

Sudden emergence and rapid spread of COVID-19 created an inevitable need for expansion of the COVID-19 laboratory testing network across the world. The strategy to test-track-treat was advocated for quick detection and containment of the disease. Being the second most populous country in the world, India was challenged to make COVID-19 testing available and accessible in all parts of the country. The molecular laboratory testing network was augmented expeditiously, and number of laboratories was increased from one in January 2020 to 2951 till mid-September, 2021. This rapid expansion warranted the need to have inbuilt systems of quality control/ quality assurance. In addition to the ongoing inter-laboratory quality control (ILQC), India implemented an External Quality Assurance Program (EQAP) with assistance from World Health Organization (WHO) and Royal College of Pathologists, Australasia. Out of the 953 open system rRTPCR laboratories in both public and private sector who participated in the first round of EQAP, 891(93.4%) laboratories obtained a passing score of > = 80%. The satisfactory performance of Indian COVID-19 testing laboratories has boosted the confidence of the public and policy makers in the quality of testing. ILQC and EQAP need to continue to ensure adherence of the testing laboratories to the desired quality standards.


Subject(s)
COVID-19 Testing/standards , COVID-19/diagnosis , Clinical Laboratory Techniques/standards , Laboratories/standards , Mass Screening/standards , Quality Assurance, Health Care/standards , Reverse Transcriptase Polymerase Chain Reaction/standards , COVID-19/epidemiology , COVID-19/genetics , COVID-19/virology , Humans , India/epidemiology , Quality Control , SARS-CoV-2/genetics , SARS-CoV-2/isolation & purification , Specimen Handling/methods
6.
Front Big Data ; 4: 790158, 2021.
Article in English | MEDLINE | ID: covidwho-1581366

ABSTRACT

COVID-19 is an ongoing pandemic, which has already claimed millions of lives worldwide. In the absence of prior information on the pandemic, the governments can use generated testing data to drive policy decisions. Thus, a one-stop repository is essential to ensure sharing of clean, de-duplicated, and updated records to all the stakeholders. In India, the government initiated the testing through a network of VRDLs headed by the Indian Council of Medical Research (ICMR). Initially, the generated data were captured and shared in Excel sheets. As the number of cases increased, there was a need for a data management system to ensure reliable and up-to-date data to drive policy decisions. Thus, the data management team at ICMR initiated the development of a national COVID-19 testing data management tool that is currently maintaining all the data in a central hub. The first version of the tool was released in March 2020 and was subsequently modified with the changing testing guidelines and strategies. On completing one and a half years of managing the data and collecting approximately 550 million records, the team analyzed the challenges faced and the strategies used to ensure a seamless flow of data to the system and its real-time analysis. In this study, the entire duration of the pandemic has been divided into four different phases based on the resourcefulness of the country. Since the pandemic is currently ongoing, this study can be useful for countries in a different phase of pandemic facing similar challenges.

7.
Environ Health ; 20(1): 120, 2021 11 19.
Article in English | MEDLINE | ID: covidwho-1526639

ABSTRACT

BACKGROUND: The Coronavirus disease 2019 (COVID-19) pandemic poses a serious public health concern worldwide. Certain regions of the globe were severely affected in terms of prevalence and mortality than other. Although the cause for this pattern is not clearly understood, lessons learned from previous epidemics and emerging evidences suggest the major role of ecological factors like ambient air pollutants (AAP) and meteorological parameters in increased COVID-19 incidence. The present study aimed to understand the impact of these factors on SARS-CoV-2 transmission and their associated mortality in major cities of India. METHODS: This study used secondary AAP, meteorological and COVID-19 data from official websites for the period January-November 2020, which were divided into Pre-lockdown (January-March 2020), Phase I (April to June 2020) and Phase II (July to November 2020) in India. After comprehensive screening, five major cities that includes 48 CPCB monitoring stations collecting daily data of ambient temperature, particulate matter PM2.5 and 10 were analysed. Spearman and Kendall's rank correlation test was performed to understand the association between SARS-CoV-2 transmission and AAP and, meteorological variables. Similarly, case fatality rate (CFR) was determined to compute the correlation between AAP and COVID-19 related morality. RESULTS: The level of air pollutants in major cities were significantly reduced during Phase I compared to Pre-lock down and increased upon Phase II in all the cities. During the Phase II in Delhi, the strong significant positive correlation was observed between the AAP and SARS-CoV-2 transmission. However, in Bengaluru, Hyderabad, Kolkata and Mumbai AAP levels were moderate and no correlation was noticed. The relation between AT and SARS-CoV-2 transmission was inconclusive as both positive and negative correlation observed. In addition, Delhi and Kolkata showed a positive association between long-term exposure to the AAP and COVID-19 CFR. CONCLUSION: Our findings support the hypothesis that the particulate matter upon exceeding the satisfactory level serves as an important cofactor in increasing the risk of SARS-CoV-2 transmission and related mortality. These findings would help public health experts to understand the SARS-CoV-2 transmission against ecological variables in India and provides supporting evidence to healthcare policymakers and government agencies for formulating strategies to combat the COVID-19.


Subject(s)
Air Pollutants , COVID-19 , Meteorological Concepts , Air Pollutants/analysis , COVID-19/mortality , COVID-19/transmission , Cities , Environmental Monitoring , Humans , India/epidemiology , Particulate Matter/analysis
8.
Vaccine ; 39(37): 5254-5256, 2021 08 31.
Article in English | MEDLINE | ID: covidwho-1331286

ABSTRACT

Up until now, countries have adopted a 'isolate-test-treat-trace' strategy to contain the COVID-19 pandemic. The next critical intervention in the fight against COVID-19 will be effective delivery of safe and efficacious vaccines. Various countries such as the USA, the UK, Canada, Israel, etc., have started administering vaccines to priority population groups. India is gearing up its critical components of the vaccine delivery system to effectively deliver vaccines across the country and has prioritized certain population groups to whom the vaccine will be administered. Considering India's ambitious target to vaccinate close to 300 million people in the first phase of the vaccination drive with limited initial supply (which will be ramped up gradually), it is critical for stakeholders at all the levels - national, state and district - to understand the estimated need for vaccines across geographies based on the vulnerable population and disease epidemiology with the objective of preventing maximum number of future infections from the disease. This paper aims to describe a comprehensive geo-prioritization framework based on existing prevalence of COVID-19, high-risk co-morbidities, and demographic analysis to identify states/districts that could be most in need of the COVID-19 vaccines.


Subject(s)
COVID-19 Vaccines , COVID-19 , Humans , India/epidemiology , Pandemics , SARS-CoV-2 , Vaccination
SELECTION OF CITATIONS
SEARCH DETAIL